| 8.01 -0.44 (-5.21%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.46 | 1-year : | 14.51 |
| Resists | First : | 9.81 | Second : | 12.43 |
| Pivot price | 9.3  |
|||
| Supports | First : | 5.57 | Second : | 4.64 |
| MAs | MA(5) : | 8.61 |
MA(20) : | 8.56 |
| MA(100) : | 4.16 |
MA(250) : | 3.25 |
|
| MACD | MACD : | 0.7 |
Signal : | 1 |
| %K %D | K(14,3) : | 37.1 |
D(3) : | 41.6 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 12.43 | Low : | 1.83 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IBRX ] has closed above bottom band by 13.5%. Bollinger Bands are 70.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.39 - 8.48 | 8.48 - 8.52 |
| Low: | 7.61 - 7.71 | 7.71 - 7.77 |
| Close: | 7.89 - 8.06 | 8.06 - 8.16 |
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Tue, 10 Mar 2026
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) - Yahoo Finance
Mon, 09 Mar 2026
ImmunityBio (NASDAQ:IBRX) Shares Down 2.5% - Should You Sell? - MarketBeat
Mon, 09 Mar 2026
IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits
Mon, 09 Mar 2026
FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan
Sat, 07 Mar 2026
Vanguard Group Inc. Boosts Stock Position in ImmunityBio, Inc. $IBRX - MarketBeat
Sat, 07 Mar 2026
Rafferty Asset Management LLC Grows Stake in ImmunityBio, Inc. $IBRX - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1,030 (M) |
| Shares Float | 379 (M) |
| Held by Insiders | 63.6 (%) |
| Held by Institutions | 16.8 (%) |
| Shares Short | 134,700 (K) |
| Shares Short P.Month | 127,000 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.5 |
| Profit Margin | 0 % |
| Operating Margin | -169 % |
| Return on Assets (ttm) | -36.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 407 % |
| Gross Profit (p.s.) | 0.1 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | -0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -305 (M) |
| Levered Free Cash Flow | -213 (M) |
| PE Ratio | -21.08 |
| PEG Ratio | 0 |
| Price to Book value | -16.03 |
| Price to Sales | 72.82 |
| Price to Cash Flow | -27.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|